MCID: BSL007
MIFTS: 65

Basal Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Basal Cell Carcinoma

MalaCards integrated aliases for Basal Cell Carcinoma:

Name: Basal Cell Carcinoma 12 77 38 30 6 15 17 74
Basal Cell Neoplasm 12 17 74
Basal Cell Cancer 12 56 74
Malignant Basal Cell Tumor 12 74
Experimental Organism Basal Cell Carcinoma 74
Nodulo-Ulcerative Basal Cell Carcinoma 74
Malignant Basal Cell Neoplasm 12
Basal Cell Carcinoma of Skin 12
Epithelioma Basal Cell 12
Carcinoma, Basal Cell 45
Neoplasms, Basal Cell 45
Carcinoma Basal Cell 56
Basal Cell Tumor 12
Rodent Ulcer 12

Classifications:



Summaries for Basal Cell Carcinoma

Disease Ontology : 12 A skin carcinoma affecting basal cells.

MalaCards based summary : Basal Cell Carcinoma, also known as basal cell neoplasm, is related to basal cell carcinoma 1 and basal cell carcinoma, multiple. An important gene associated with Basal Cell Carcinoma is SMO (Smoothened, Frizzled Class Receptor), and among its related pathways/superpathways are Basal cell carcinoma and G-Beta Gamma Signaling. The drugs Aminolevulinic acid and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and lung, and related phenotypes are growth/size/body region and digestive/alimentary

Wikipedia : 77 Basal-cell carcinoma (BCC), also known as basal-cell cancer, is the most common type of skin cancer. It... more...

Related Diseases for Basal Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 397)
# Related Disease Score Top Affiliating Genes
1 basal cell carcinoma 1 35.1 BCC1 PTCH1
2 basal cell carcinoma, multiple 34.6 PTCH1 PTCH2 SMO
3 basal cell nevus syndrome 34.4 GLI1 GLI2 PTCH1 PTCH2 SHH SMO
4 ameloblastoma 31.0 GLI1 PTCH1 SMO
5 keratocystic odontogenic tumor 31.0 GLI1 PTCH1 SHH SMO SUFU TP53
6 medulloblastoma 30.9 CDKN2B-AS1 CTNNB1 GLI1 GLI2 PTCH1 PTCH2
7 childhood medulloblastoma 30.3 PTCH1 SUFU TP53
8 spiradenoma 30.1 CYLD TP53
9 nodular basal cell carcinoma 12.7
10 basal cell carcinoma, infundibulocystic 12.7
11 pigmented basal cell carcinoma 12.6
12 metatypical basal cell carcinoma 12.6
13 micronodular basal cell carcinoma 12.6
14 basal cell carcinoma 7 12.5
15 penis basal cell carcinoma 12.5
16 superficial basal cell carcinoma 12.5
17 anal margin basal cell carcinoma 12.5
18 morpheaform basal cell carcinoma 12.5
19 vulva basal cell carcinoma 12.4
20 adenoid basal cell carcinoma 12.4
21 cystic basal cell carcinoma 12.4
22 clear cell basal cell carcinoma 12.4
23 sarcomatoid basal cell carcinoma 12.4
24 basal cell carcinoma 5 12.4
25 basal cell carcinoma 2 12.4
26 basal cell carcinoma 3 12.4
27 external ear basal cell carcinoma 12.4
28 vulvar basal cell carcinoma 12.4
29 scrotum basal cell carcinoma 12.4
30 infiltrative basal cell carcinoma 12.4
31 fibroepithelial basal cell carcinoma 12.4
32 bazex syndrome 12.3
33 basal cell carcinoma 4 12.3
34 basal cell carcinoma 6 12.3
35 follicular basal cell carcinoma 12.3
36 signet ring basal cell carcinoma 12.3
37 sebaceous basal cell carcinoma 12.2
38 rombo syndrome 12.1
39 brooke-spiegler syndrome 11.4
40 multiple familial trichoepithelioma 11.4
41 prostate cancer 11.4
42 bap1 tumor predisposition syndrome 11.4
43 adamantinoid basal cell epithelioma 11.3
44 trichoepithelioma, multiple familial, 1 11.2
45 epidermolysis bullosa simplex, dowling-meara type 11.1
46 prostate cancer, hereditary, 1 11.1
47 prostate cancer, hereditary, 12 11.1
48 prostate cancer, hereditary, 13 11.1
49 prostate cancer, hereditary, 11 11.1
50 prostate cancer, hereditary, 2 11.1

Graphical network of the top 20 diseases related to Basal Cell Carcinoma:



Diseases related to Basal Cell Carcinoma

Symptoms & Phenotypes for Basal Cell Carcinoma

MGI Mouse Phenotypes related to Basal Cell Carcinoma:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.22 CTNNB1 CYLD GLI1 GLI2 MC1R PALB2
2 digestive/alimentary MP:0005381 10.21 CTNNB1 CYLD GLI1 GLI2 PTCH1 PTCH2
3 craniofacial MP:0005382 10.18 CTNNB1 GLI1 GLI2 MC1R PTCH1 SHH
4 embryo MP:0005380 10.15 CTNNB1 GLI1 GLI2 PALB2 PTCH1 SHH
5 limbs/digits/tail MP:0005371 10.14 CTNNB1 CYLD GLI1 GLI2 MC1R PALB2
6 integument MP:0010771 10.13 CTNNB1 CYLD GLI2 MC1R PALB2 PTCH1
7 neoplasm MP:0002006 10.02 CTNNB1 CYLD GLI1 MC1R PALB2 PTCH1
8 hearing/vestibular/ear MP:0005377 10 CTNNB1 GLI2 MC1R PTCH1 SHH SMO
9 muscle MP:0005369 9.91 CTNNB1 GLI2 PTCH1 PTCH2 SHH SMO
10 no phenotypic analysis MP:0003012 9.86 CTNNB1 GLI1 GLI2 MC1R PTCH1 SHH
11 normal MP:0002873 9.85 CTNNB1 CYLD GLI1 GLI2 PTCH1 PTCH2
12 pigmentation MP:0001186 9.35 CTNNB1 MC1R PTCH1 SUFU TP53
13 respiratory system MP:0005388 9.28 CTNNB1 CYLD GLI1 GLI2 PTCH1 SHH

Drugs & Therapeutics for Basal Cell Carcinoma

Drugs for Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 299)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
3
Everolimus Approved Phase 4,Phase 1 159351-69-6 6442177 70789204
4
Sirolimus Approved, Investigational Phase 4,Phase 1 53123-88-9 46835353 6436030 5284616
5
Tacrolimus Approved, Investigational Phase 4,Phase 1 104987-11-3 445643 439492 6473866
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
7
Mycophenolic acid Approved Phase 4 24280-93-1 446541
8
Azathioprine Approved Phase 4 446-86-6 2265
9 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 interferons Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
15 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Antiviral Agents Phase 4,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Interferon-alpha Phase 4
21 Calcineurin Inhibitors Phase 4,Phase 1
22 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Early Phase 1
23 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
24 Cyclosporins Phase 4
25 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
26 polysaccharide-K Phase 4
27
Zinc Approved, Investigational Phase 3 7440-66-6 32051
28
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
29
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
31
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
32
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
33
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
34
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
35
Histamine Approved, Investigational Phase 3,Not Applicable 51-45-6 774
36
Promethazine Approved, Investigational Phase 3 60-87-7 4927
37
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
38
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
39
Sodium Citrate Approved, Investigational Phase 3 68-04-2
40
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
41
Tamoxifen Approved Phase 3 10540-29-1 2733526
42
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3 33069-62-4 36314
43
Trastuzumab Approved, Investigational Phase 2, Phase 3,Phase 3,Early Phase 1 180288-69-1 9903
44
Epirubicin Approved Phase 2, Phase 3,Phase 1 56420-45-2 41867
45
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 114977-28-5 148124
46
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 1 154361-50-9 60953
47
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
48
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
49
Triamcinolone Approved, Vet_approved Phase 3,Phase 2 124-94-7 31307
50
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Early Phase 1 6055-19-2, 50-18-0 2907

Interventional clinical trials:

(show top 50) (show all 335)
# Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Unknown status NCT00803907 Phase 4 Imiquimod 5% cream
3 Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage Completed NCT00314756 Phase 4 imiquimod
4 Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC) Completed NCT00581425 Phase 4
5 Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
6 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
7 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Recruiting NCT02436408 Phase 4 Vismodegib
8 Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
9 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
10 Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control Unknown status NCT00663650 Phase 3
11 Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream Completed NCT00189306 Phase 3 Imiquimod 5% cream
12 A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
13 Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
14 Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
15 A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence Completed NCT00129519 Phase 3 Imiquimod 5% cream
16 Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma Completed NCT01212549 Phase 3
17 Metvix PDT in Patients With "High Risk" Basal Cell Carcinoma Completed NCT00473343 Phase 3
18 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed NCT00066872 Phase 3 imiquimod
19 Fractional CO2 Laser Assisted Photodynamic Therapy Completed NCT01260987 Phase 2, Phase 3 Conventional photodynamic therapy;Fractional CO2 laser assisted PDT
20 PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma Completed NCT00472043 Phase 3
21 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
22 Aldara for the Treatment of Large and/or Multiple sBCC Completed NCT00189280 Phase 3 Imiquimod
23 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
24 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
25 Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals. Completed NCT00272428 Phase 3
26 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
27 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
28 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
29 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
30 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
31 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
32 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
33 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
34 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01362140 Phase 3 Darbepoetin alfa;Placebo
35 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
36 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). Recruiting NCT03573401 Phase 3
37 Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome Recruiting NCT03703310 Phase 3 Patidegib Topical Gel, 2%;Patidegib Topical Gel, Vehicle
38 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod
39 A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin Recruiting NCT03085368 Phase 2, Phase 3 lapatinib/herceptin
40 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02488967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
41 Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma Active, not recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
42 Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy Active, not recruiting NCT02144077 Phase 3 BF-200 ALA;methyl-aminolevulinate
43 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
44 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
45 Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin. Terminated NCT00049959 Phase 3 verteporfin PDT
46 Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients Terminated NCT01532453 Phase 3
47 Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) Withdrawn NCT03070691 Phase 2, Phase 3 LDE225B;Vehicle
48 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
49 Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight Unknown status NCT01349361 Phase 2
50 Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride

Search NIH Clinical Center for Basal Cell Carcinoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: carcinoma, basal cell

Genetic Tests for Basal Cell Carcinoma

Genetic tests related to Basal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Basal Cell Carcinoma 30

Anatomical Context for Basal Cell Carcinoma

MalaCards organs/tissues related to Basal Cell Carcinoma:

42
Skin, Breast, Lung, Kidney, Bone, Brain, Prostate

Publications for Basal Cell Carcinoma

Articles related to Basal Cell Carcinoma:

(show top 50) (show all 3625)
# Title Authors Year
1
Extensive bony metastases from facial metatypical basal cell carcinoma: a case report. ( 30598320 )
2019
2
Dermoscopic features of acral basal cell carcinoma. ( 30604521 )
2019
3
Targeting tryptophan transport and breakdown in basal cell carcinoma. ( 30604530 )
2019
4
Quantitative survey into value clarification of discussed treatment options among patients treated for basal cell carcinoma. ( 30613956 )
2019
5
Clinical Characteristics of Basal Cell Carcinoma in African Americans: A 10-Year Retrospective Review at a Single Academic Institution. ( 30614839 )
2019
6
Basal cell carcinoma of the vulva: treatment with Mohs micrographic surgery. ( 30618159 )
2019
7
A randomised phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned. ( 30628055 )
2019
8
Comparative genomic hybridization analysis of basal cell carcinoma. ( 30629797 )
2019
9
Melanoma Within Basal Cell Carcinoma Nests Discovered During Mohs Micrographic Surgery. ( 30640782 )
2019
10
Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib re-administration in a patient with locally advanced BCC. ( 30653740 )
2019
11
Basal cell carcinoma of the prostate: A case report and review of the literature. ( 30655983 )
2019
12
Scalp basal cell carcinoma: a different entity? ( 30659714 )
2019
13
SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1-mediated PI3K/AKT signaling pathway. ( 30675221 )
2019
14
Metaplastic basal cell carcinoma developing into syringomatous carcinoma: An enigmatic case report. ( 30697801 )
2019
15
Facial site distribution of basal cell carcinoma in Japanese. ( 30698878 )
2019
16
Mixed cranial neuropathies due to occult perineural invasion of basal cell carcinoma. ( 30705997 )
2019
17
Loss of primary cilia drives switching from Hedgehog to Ras/MAPK pathway in resistant basal cell carcinoma. ( 30707899 )
2019
18
Tissue-sparing properties of Mohs micrographic surgery for infiltrative basal cell carcinoma. ( 30710602 )
2019
19
Extremity nevus count is an independent risk factor for basal cell carcinoma and melanoma, but not squamous cell carcinoma. ( 30713015 )
2019
20
Basal Cell Carcinoma Pathology Requests and Reports Are Lacking Important Information. ( 30719355 )
2019
21
Effect of endostatin on proliferation, invasion and epithelial-mesenchymal transition of basal cell carcinoma cell A431. ( 30720196 )
2019
22
Peritumoral clefting as a key feature in differentiating basal cell carcinoma from trichoblastoma through in-vivo reflectance confocal microscopy. ( 30720895 )
2019
23
Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single center experience. ( 30720897 )
2019
24
Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma. ( 30725082 )
2019
25
Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma. ( 30725085 )
2019
26
Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma. ( 30725088 )
2019
27
Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma-Reply. ( 30725098 )
2019
28
Patterns of proliferation and apoptosis in different subtypes of basal cell carcinoma, adjacent epidermis, and recurrent forms. ( 30726478 )
2019
29
PRISModegib: the use of the PRISM test to assess the Health-Related Quality of Life of patients with Locally Advanced Basal Cell Carcinoma undergoing Hedgehog Pathway Inhibitor Therapy. ( 30737996 )
2019
30
Diagnosis and Management of Basal Cell Carcinoma. ( 30741348 )
2019
31
Nevoid Basal Cell Carcinoma Syndrome: PTCH1 Mutation Profile and Expression of Genes Involved in the Hedgehog Pathway in Argentinian Patients. ( 30754660 )
2019
32
Locally destructive metastatic basal cell carcinoma. ( 30758350 )
2019
33
S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-up. ( 30762963 )
2019
34
Successful Utilization of Optical Coherence Tomography as a Non-Invasive, Bedside Imaging Technique To Identify Residual Nodular Basal Cell Carcinoma at Well-Healed and Clinically Unidentifiable Biopsy Site. ( 30771419 )
2019
35
Live remote control of an in vivo reflectance confocal microscope allows diagnosis of basal cell carcinoma at the bedside on a patient 2,500 miles away: A novel tele-RCM approach. ( 30771424 )
2019
36
Vulvar basal cell carcinoma: clinical features and treatment outcomes from a tertiary-care centre. ( 30773599 )
2019
37
Nodular Cystic Variant of Basal Cell Carcinoma: Perfect Correlation Between Histopathology and Confocal Microscopy. ( 30775152 )
2019
38
Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib ( 30794363 )
2019
39
High-risk basal cell carcinoma excision in primary care: a retrospective observational study of compliance with NICE guidance. ( 30798290 )
2019
40
Basal Cell Carcinoma: Additional Subtypes and Therapeutic Advances. ( 30802559 )
2019
41
A healthy individual with a homozygous PTCH2 frameshift variant: Are variants of PTCH2 associated with nevoid basal cell carcinoma syndrome? ( 30820324 )
2019
42
Can optical coherence tomography improve the management of basal cell carcinoma? ( 30821394 )
2019
43
What is the Prevalence of Undiagnosed Nevoid Basal Cell Carcinoma Syndrome in Children With an Odontogenic Keratocyst? ( 30826393 )
2019
44
Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase. ( 30827262 )
2019
45
Oncologic outcomes after surgery for locally aggressive basal cell carcinoma of the head and neck. ( 30835833 )
2019
46
'Eternal sunshine of the spotless islands': how dermoscopy may influence confocal microscopy when dealing with squamous cells carcinoma simulating basal cell carcinoma. ( 30851204 )
2019
47
Neurofolicullar hamartoma presenting as a rare adnexal neoplasm in association with basal cell carcinoma. ( 30858950 )
2019
48
Investigation of Interleukin-17 Gene Polymorphisms and Serum Levels in Patients with Basal Cell Carcinoma of the Skin. ( 30864555 )
2019
49
Telomere length, arsenic exposure and risk of basal cell carcinoma of skin. ( 30874287 )
2019
50
Characterisation of resistance mechanisms developed by basal cell carcinoma cells in response to repeated cycles of Photodynamic Therapy. ( 30886381 )
2019

Variations for Basal Cell Carcinoma

ClinVar genetic disease variations for Basal Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PALB2 NM_024675.3(PALB2): c.1451T> A (p.Leu484Ter) single nucleotide variant Pathogenic/Likely pathogenic rs786203714 GRCh37 Chromosome 16, 23646416: 23646416
2 PALB2 NM_024675.3(PALB2): c.1451T> A (p.Leu484Ter) single nucleotide variant Pathogenic/Likely pathogenic rs786203714 GRCh38 Chromosome 16, 23635095: 23635095
3 SMO NM_005631.4(SMO): c.1417G> C (p.Asp473His) single nucleotide variant Pathogenic rs17710891 GRCh37 Chromosome 7, 128849189: 128849189
4 SMO NM_005631.4(SMO): c.1417G> C (p.Asp473His) single nucleotide variant Pathogenic rs17710891 GRCh38 Chromosome 7, 129209348: 129209348
5 PTCH1 NM_000264.4(PTCH1): c.3836_3837del (p.Pro1279Leufs) deletion Uncertain significance GRCh38 Chromosome 9, 95447419: 95447420
6 PTCH1 NM_000264.4(PTCH1): c.3836_3837del (p.Pro1279Leufs) deletion Uncertain significance GRCh37 Chromosome 9, 98209701: 98209702

Cosmic variations for Basal Cell Carcinoma:

9 (show top 50) (show all 687)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM3691166 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 0
2 COSM6926860 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 0
3 COSM6926861 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 0
4 COSM6969201 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 0
5 COSM6953811 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 0
6 COSM6926862 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 0
7 COSM6936924 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 0
8 COSM212945 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 0
9 COSM6936922 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 0
10 COSM6926855 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 0
11 COSM6953809 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 0
12 COSM6912933 TRAF7 skin,NS,carcinoma,basal cell carcinoma c.1802C>T p.T601I 16:2176104-2176104 0
13 COSM6949578 TP63 skin,NS,carcinoma,basal cell carcinoma c.1922C>T p.A641V 3:189894381-189894381 0
14 COSM44097 TP53 skin,NS,carcinoma,basal cell carcinoma c.530C>T p.P177L 17:7675082-7675082 0
15 COSM44071 TP53 skin,NS,carcinoma,basal cell carcinoma c.955A>G p.K319E 17:7673573-7673573 0
16 COSM44096 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>G p.P250A 17:7674215-7674215 0
17 COSM45751 TP53 skin,NS,carcinoma,basal cell carcinoma c.511G>C p.E171Q 17:7675101-7675101 0
18 COSM10768 TP53 skin,NS,carcinoma,basal cell carcinoma c.535C>T p.H179Y 17:7675077-7675077 0
19 COSM10887 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>G p.P278R 17:7673787-7673787 0
20 COSM10728 TP53 skin,NS,carcinoma,basal cell carcinoma c.839G>A p.R280K 17:7673781-7673781 0
21 COSM45739 TP53 skin,NS,carcinoma,basal cell carcinoma c.677G>C p.G226A 17:7674286-7674286 0
22 COSM44295 TP53 skin,NS,carcinoma,basal cell carcinoma c.993+1G>A p.? 17:7673534-7673534 0
23 COSM43778 TP53 skin,NS,carcinoma,basal cell carcinoma c.713G>T p.C238F 17:7674250-7674250 0
24 COSM10939 TP53 skin,NS,carcinoma,basal cell carcinoma c.832C>T p.P278S 17:7673788-7673788 0
25 COSM10650 TP53 skin,NS,carcinoma,basal cell carcinoma c.529C>T p.P177S 17:7675083-7675083 0
26 COSM43665 TP53 skin,NS,carcinoma,basal cell carcinoma c.746G>C p.R249T 17:7674217-7674217 0
27 COSM10662 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
28 COSM45774 TP53 skin,NS,carcinoma,basal cell carcinoma c.899C>G p.P300R 17:7673721-7673721 0
29 COSM10749 TP53 skin,NS,carcinoma,basal cell carcinoma c.830G>T p.C277F 17:7673790-7673790 0
30 COSM11449 TP53 skin,NS,carcinoma,basal cell carcinoma c.388C>T p.L130F 17:7675224-7675224 0
31 COSM10660 TP53 skin,NS,carcinoma,basal cell carcinoma c.818G>A p.R273H 17:7673802-7673802 0
32 COSM44068 TP53 skin,NS,carcinoma,basal cell carcinoma c.532C>A p.H178N 17:7675080-7675080 0
33 COSM10771 TP53 skin,NS,carcinoma,basal cell carcinoma c.749C>T p.P250L 17:7674214-7674214 0
34 COSM11152 TP53 skin,NS,carcinoma,basal cell carcinoma c.700T>C p.Y234H 17:7674263-7674263 0
35 COSM43582 TP53 skin,NS,carcinoma,basal cell carcinoma c.454C>T p.P152S 17:7675158-7675158 0
36 COSM45834 TP53 skin,NS,carcinoma,basal cell carcinoma c.409C>A p.L137M 17:7675203-7675203 0
37 COSM10905 TP53 skin,NS,carcinoma,basal cell carcinoma c.451C>T p.P151S 17:7675161-7675161 0
38 COSM10654 TP53 skin,NS,carcinoma,basal cell carcinoma c.637C>T p.R213* 17:7674894-7674894 0
39 COSM45424 TP53 skin,NS,carcinoma,basal cell carcinoma c.781A>T p.S261C 17:7674182-7674182 0
40 COSM10648 TP53 skin,NS,carcinoma,basal cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
41 COSM6932 TP53 skin,NS,carcinoma,basal cell carcinoma c.733G>A p.G245S 17:7674230-7674230 0
42 COSM10812 TP53 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.S241F 17:7674241-7674241 0
43 COSM10656 TP53 skin,NS,carcinoma,basal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 0
44 COSM10659 TP53 skin,NS,carcinoma,basal cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
45 COSM10794 TP53 skin,NS,carcinoma,basal cell carcinoma c.796G>A p.G266R 17:7673824-7673824 0
46 COSM44552 TP53 skin,NS,carcinoma,basal cell carcinoma c.509C>T p.T170M 17:7675103-7675103 0
47 COSM10704 TP53 skin,NS,carcinoma,basal cell carcinoma c.844C>T p.R282W 17:7673776-7673776 0
48 COSM10726 TP53 skin,NS,carcinoma,basal cell carcinoma c.856G>A p.E286K 17:7673764-7673764 0
49 COSM6549 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>T p.R248L 17:7674220-7674220 0
50 COSM45304 TP53 skin,NS,carcinoma,basal cell carcinoma c.375+1G>A p.? 17:7675993-7675993 0

Copy number variations for Basal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 256908 9 98205264 98279247 Mutation PTCH Basal cell carcinoma

Expression for Basal Cell Carcinoma

Search GEO for disease gene expression data for Basal Cell Carcinoma.

Pathways for Basal Cell Carcinoma

Pathways related to Basal Cell Carcinoma according to KEGG:

38
# Name Kegg Source Accession
1 Basal cell carcinoma hsa05217

Pathways related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SMO
2 12.7 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SHH
3
Show member pathways
12.42 GLI1 GLI2 PTCH1 SHH SMO SUFU
4
Show member pathways
12.21 PTCH1 PTCH2 SHH SMO
5 12.13 CTNNB1 PTCH1 SHH SMO TP53
6 11.82 CTNNB1 CYLD GLI1 GLI2 PTCH1 PTCH2
7
Show member pathways
11.81 GLI1 GLI2 PTCH1 PTCH2 SHH SMO
8
Show member pathways
11.77 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SHH
9 11.36 GLI1 GLI2 PTCH1 SHH SMO
10
Show member pathways
11.17 GLI2 PTCH1 PTCH2 SHH SMO
11 11.13 GLI1 GLI2 SHH
12 10.4 PTCH1 SHH

GO Terms for Basal Cell Carcinoma

Cellular components related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cilium GO:0005929 9.55 GLI1 GLI2 PTCH1 SMO SUFU
2 ciliary base GO:0097546 9.13 GLI1 GLI2 SUFU
3 ciliary tip GO:0097542 9.02 CYLD GLI1 GLI2 SMO SUFU

Biological processes related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.97 CTNNB1 GLI2 PALB2 PTCH1 SMO
2 kidney development GO:0001822 9.92 CTNNB1 GLI2 SHH
3 anterior/posterior pattern specification GO:0009952 9.92 GLI2 SHH SMO
4 osteoblast differentiation GO:0001649 9.92 GLI1 GLI2 SMO
5 lung development GO:0030324 9.91 CTNNB1 GLI1 GLI2 SHH
6 canonical Wnt signaling pathway GO:0060070 9.9 CTNNB1 GLI1 SHH
7 determination of left/right symmetry GO:0007368 9.9 SHH SMO SUFU
8 heart looping GO:0001947 9.88 SHH SMO SUFU
9 vasculogenesis GO:0001570 9.88 CTNNB1 SHH SMO
10 embryonic digit morphogenesis GO:0042733 9.87 CTNNB1 GLI2 SHH
11 branching involved in ureteric bud morphogenesis GO:0001658 9.87 CTNNB1 PTCH1 SHH
12 positive regulation of smoothened signaling pathway GO:0045880 9.83 GLI1 SHH SMO
13 developmental growth GO:0048589 9.82 GLI2 SHH SMO
14 positive regulation of mesenchymal cell proliferation GO:0002053 9.81 CTNNB1 SHH SMO
15 pattern specification process GO:0007389 9.81 GLI2 PTCH1 SHH SMO
16 hair follicle morphogenesis GO:0031069 9.8 CTNNB1 SHH SMO
17 negative regulation of smoothened signaling pathway GO:0045879 9.8 PTCH1 PTCH2 SUFU
18 odontogenesis of dentin-containing tooth GO:0042475 9.8 CTNNB1 GLI2 SHH SMO
19 proximal/distal pattern formation GO:0009954 9.79 CTNNB1 GLI1 GLI2
20 regulation of smoothened signaling pathway GO:0008589 9.79 GLI1 GLI2 PTCH1
21 skin development GO:0043588 9.78 CTNNB1 PTCH2 SHH SUFU
22 positive regulation of neuroblast proliferation GO:0002052 9.77 CTNNB1 SHH SMO
23 hindbrain development GO:0030902 9.77 CTNNB1 GLI2 SHH
24 spinal cord motor neuron differentiation GO:0021522 9.76 GLI2 PTCH1 SHH
25 embryonic organ development GO:0048568 9.76 PALB2 PTCH1 SHH SMO
26 male genitalia development GO:0030539 9.75 CTNNB1 SHH
27 osteoblast development GO:0002076 9.75 GLI2 SHH
28 negative regulation of chondrocyte differentiation GO:0032331 9.75 CTNNB1 GLI2
29 cell fate specification GO:0001708 9.75 CTNNB1 SHH SMO
30 epithelial tube branching involved in lung morphogenesis GO:0060441 9.74 CTNNB1 SHH
31 cellular response to cholesterol GO:0071397 9.74 PTCH1 SMO
32 digestive tract morphogenesis GO:0048546 9.74 GLI1 SHH
33 ectoderm development GO:0007398 9.74 CTNNB1 SHH
34 regulation of osteoblast differentiation GO:0045667 9.73 CTNNB1 GLI1
35 mammary gland epithelial cell differentiation GO:0060644 9.73 PTCH1 SMO
36 thalamus development GO:0021794 9.73 SHH SMO
37 commissural neuron axon guidance GO:0071679 9.73 PTCH1 SMO
38 positive regulation of T cell differentiation in thymus GO:0033089 9.73 GLI2 SHH
39 cell fate determination GO:0001709 9.73 CTNNB1 PTCH1 PTCH2
40 embryonic foregut morphogenesis GO:0048617 9.72 CTNNB1 SHH
41 positive regulation of skeletal muscle tissue development GO:0048643 9.72 CTNNB1 SHH
42 lung-associated mesenchyme development GO:0060484 9.72 CTNNB1 SHH
43 positive regulation of epidermal cell differentiation GO:0045606 9.71 PTCH1 PTCH2
44 somite development GO:0061053 9.71 PTCH1 SHH SMO
45 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.7 GLI2 PTCH1
46 mammary gland duct morphogenesis GO:0060603 9.7 GLI2 PTCH1
47 prostate gland development GO:0030850 9.7 GLI1 PTCH1 SHH
48 epithelial-mesenchymal cell signaling GO:0060684 9.69 SHH SMO
49 hindgut morphogenesis GO:0007442 9.69 GLI2 SHH
50 trachea morphogenesis GO:0060439 9.68 CTNNB1 SHH

Molecular functions related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hedgehog family protein binding GO:0097108 9.26 PTCH1 PTCH2
2 hedgehog receptor activity GO:0008158 9.16 PTCH1 PTCH2
3 smoothened binding GO:0005119 8.96 PTCH1 PTCH2
4 patched binding GO:0005113 8.8 PTCH1 SHH SMO

Sources for Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....